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Abstract
Corneal Langerhans cells (LCs) offer the opportunity to gain insight into the activity of the innate immunity. We
examined the density and the distribution of LCs and compared the results with dry-eye parameters in rheumatoid
arthritis (RA). Fifty-two RA patients with various degrees of disease activity and 24 healthy subjects were enrolled.
Peripheral and central LC number and morphology were assessed with in vivo laser confocal microscopy. In addition,
ocular surface disease index (OSDI), lid parallel conjunctival folds, Schirmer test, and tear break-up time (TBUT) were
evaluated. The prevalence of central and peripheral LC, and the central LC morphology values (LCM) were higher than
normal in RA. Within the RA group, LC prevalence and morphology were not affected by disease activity. However,
patients on anti-TNF or glucocorticosteroid (GCS) therapy exhibited normal LCM, and normal central and peripheral LC
density. OSDI was higher and TBUT was lower than normal in RA. The alteration of LC in RA suggests an active
inflammatory process in the cornea, which may reflect an increased activation state of the innate immune system—even
in inactive stages of RA and without ocular symptoms. The results also indicate ocular effects of GCS therapy in RA.
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Introduction
Although the predominant feature of rheumatoid arth-
ritis (RA) is joint involvement, further extra-articular
manifestations, including ocular involvement, may also
be present. The most common ocular problems in RA
are sicca symptoms and about 10% of RA patients
develop secondary Sjögren’s syndrome.1 Episcleritis,
scleritis and a variety of corneal changes, including
keratitis and keratoconjunctivitis sicca, may also
occur. The cells participating in these processes, how-
ever, are poorly clarified. The highly potent antigen-
presenting dendritic cells, the so-called corneal
Langerhans cells (LCs), act as potent inducers and
regulators of local corneal immune processes.2–4 They
can stimulate both primary and secondary T- and B-cell
responses. The distribution and role of LCs in the cen-
tral cornea is an issue of ongoing discussion. Several
investigators have demonstrated the presence of LCs in
the epithelium and stroma of the central cornea ex
vivo.5–7 Moreover, the presence of LCs in the central
corneal epithelium of healthy volunteers has also been
documented.6 Detailed information concerning the
maturation and migration of LCs in response to cyto-
kines and chemokines is not yet fully available,3,8,9
but some data suggest the principal role of
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3First Department of Pediatrics, Semmelweis University, Budapest,
Hungary
Corresponding author:
Attila Balog, Department of Rheumatology, Albert Szent-Györgyi Health









pro-inflammatory cytokines, including TNF-a.10,11 In
recent years new techniques that directly visualize
microscopic changes of ocular structures in vivo have
become available for clinical use. Confocal microscopy,
first described by Minsky,12 now applies a laser beam to
obtain coronal optical sections of the cornea and to
collect data even on the prevalence of certain cell sub-
types. With this new tool we characterized the presence
and distribution of LCs in the corneal epithelium of RA
patients with various disease severities.
Materials and methods
Patients
Fifty-two RA patients with variable severity and dur-
ation of disease, and 24 healthy individuals were
enrolled (see clinical characteristics in Table 1). RA
patients were classified according to the latest
American College of Rheumatology/European League
Against Rheumatism (ACR/EULAR criteria).13
Written informed consent was obtained from all sub-
jects, and our study was reviewed and approved by an
independent ethics committee of the institution. The
study adhered to the tenets of the most recent revision
of the Declaration of Helsinki. Disease activity score 28
(DAS28) was calculated at the time of the eye examin-
ation. All RA patients received at least one of the fol-
lowing disease-modifying anti-rheumatic drugs
(DMARD): methotrexate (69%), leflunomide (17%),
sulfasalazine (1%) and chloroquine (1%). Twenty-
three of 52 RA patients (44%) received an anti-TNF
agent, and 16 of 52 RA patients were also treated with
low-dose oral glucocorticoids (GCS) and DMARD
and/or anti-TNF agent together. At the time of evalu-
ation of confocal microscopic investigation, none of the
patients suffered any overt ocular symptom requiring
specific ophthalmic assistance. Patients with diabetes;
previous eye surgery; uveitis within one year prior to
examination; glaucoma; congenital, mechanical or
toxic injury of the cornea; or illnesses causing corneal
edema, haze or scars were excluded. RA patients with
secondary Sjögren’s syndrome diagnosed according to
the revised version of the European criteria for
Sjögren’s syndrome were omitted from the study.14
Patients with Schirmer test results of less than 5mm/
5min were not excluded automatically from the study if
the results of other functional tests and histology were
normal, and no anti-Ro(SSA) or anti-La(SSB) Abs
were detected.
Eye examinations
All examinations were carried out on the right eye only
in the same room among unchanged conditions.
Dry eye examinations
An ocular surface disease index (OSDI) questionnaire
was used to evaluate the subjective ocular discomfort.15
Lid parallel conjunctival folds (LIPCOF) are sub-
clinical folds of the conjunctiva, situated at the tem-
poral and nasal aspect of the bulbar conjunctiva.
Loosened conjunctiva creating folds, detectable by slit
lamp are thought to reflect dryness of the ocular sur-
face. According to the height and morphology, grading
can be made on a 0–3 scale reflecting the severity of dry
eye. LIPCOF was measured at the temporal aspect of
the lower eyelid margin during routine slit lamp exam-
ination, according to the protocol by Pult.16
The Schirmer-strip (Haag-Streit, UK, Ref: 4701001)
was used to evaluate tear production and was placed at
the temporal aspect of the lower conjunctival sac.
Values were read after 5min with the help of a ruler.
Tear break up time (TBUT) was determined after
instillation of one drop of fluorescein dye into the
lower conjunctival sac.
In vivo confocal microscopy investigations
All patients were examined with a digital corneal con-
focal laser-scanning microscope (HRT II RCM
Heidelberg Engineering Inc., Heidelberg, Germany,
Table 1. Clinical characteristics of healthy individuals and RA patients. Data are expressed as median [interquartile
range].
Characteristics Healthy individuals n¼ 24 RA patients n¼ 52
Age (years) 61 [52.5–67] 58 [49–66]
Gender (male/female) 10/14 9/43
RA duration (years) – 8 [3.75–15]
DAS28 – 2.30 [1.76–3.52]
No. of patients receiving anti-TNF-a therapy – 23 (44.2%)
No. of patients receiving DMARD therapy 29 (55.8%)
No. of patients receiving glucocorticosteroid therapy 16 (30.8%)
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Rostock Cornea Module), equipped with the in-built
software Heidelberg Eye Explorer version 1.5.10.0.
In vivo confocal microscopy (IVCM) uses helium
neon diode laser source with a wavelength of 670 nm.
The two-dimensional images captured by the IVCM
have a definition of 384 384 pixels over an area of
400 mm 400 mm, with lateral spatial resolution of
0.5 mm and a depth resolution of 1–2 mm.
Data collection
Topical anaesthetic drops (Oxybuprocaine-Humacain
0.4%, Human Pharmaceuticals, Gödöllo00, Hungary)
were applied to the right eye and confocal cornea
microscopy was carried out. Proper alignment and fix-
ation of the eye was maintained with a target mobile
red light for the contralateral eye. Sterile packaging
disposable plastic cap (TomoCap, Heidelberg,
Germany) was used to keep the distance from the
cornea to the microscope head stable. Carbomer gel
(Vidisic; Dr Mann Pharma, Berlin, Germany) was
used as coupling medium. Positioning of the objective
lens was monitored with a digital camera tangential
to the eye.
LCs were seen as hyper-reflective corpuscular par-
ticles with or without dendrite-like protrusions situated
at the level of the basal epithelial cells and the sub-basal
nerve plexus. We found LCs to have an average diam-
eter of up to 15 mm in the corneal centre. LC densities
were examined both at the centre of the cornea and its
periphery at the 6 o’clock position at a depth of 40–
60 mm from the corneal surface at the level of the basal
epithelial cell layer and sub-basal nerve plexus. Forty
images were taken and the five best-focused images
were considered for the analysis in a masked fashion.
After selection of the region of interest, cells could be
marked and the system calculated cell density automat-
ically (cell number/mm2). LC morphology (LCM) was
evaluated on a 0–3 scale, where score 1 represented LCs
without dendrites, score 2 was given to LCs with small
processes and score 3 was given to LCs with long pro-
cesses. Score 0 described the condition when the cornea
was devoid of LCs. The average LCM was calculated in
each of the figures selected and was used to describe the
maturation of the LCs at both locations of the cornea
(Figure 1).
Statistics
Data are expressed as mean SD. Comparisons
between healthy individuals and RA patients, as well
as between RA patient subgroups, were made with
Cochran-Armitage trend tests in case of ordinal vari-
ables (LCM and LIPCOF). Continuous variables were
compared using t-tests. Prior to analysis, the distri-
bution of variables were checked graphically and,
if necessary, variables were Box-Cox transformed
prior to the analysis. We tested all possible two-
way interactions (anti-TNF-a therapy*DAS28,
DAS28*glucocorticosteroid, anti-TNF-a therapy *glu-
cocorticosteroid) in the group of RA patients. None of
these interactions were significant (details not shown).
We used Spearman’s rank correlation test to investigate
correlations within groups. P-values <0.05 were con-
sidered significant. Statistical analysis was performed
using STATISTICA version 8.0 (StatSoft, Tulsa,
OK, USA).
Results
The results of functional assays can be seen in Table 2.
Of note, OSDI scores were higher and TBUT showed a
trend to be lower than normal in RA (P¼ 0.057). Tear
production showed a trend to be decreased only in RA
patients on GCS therapy (P¼ 0.074).
Confocal microscopy data
The central and peripheral corneal LC prevalence
values were higher in RA patients compared with
healthy individuals (Table 3). The central LCM values
were also higher than in controls. These data indicate
that mature dendritic cells accumulate in the cornea of
RA patients. The central LC density and the central
LCM values were increased, even in RA patients in
remission (<2.6 DAS28), as there was no difference
between RA subgroups formed according to the clinical
activity (DAS28).
We also compared the LC density and morphology
between RA subgroups formed according to therapy.
LC density values were higher in RA patients without
GCS therapy. In other words, GCS therapy restored
the increased LC density observed in RA patients
without GCS.
Discussion
To the best of our knowledge, this is the first study to
investigate the characteristics of corneal LC density and
morphology in RA. We have demonstrated increased
density and activation of dendritic cells in the cornea
of RA patients in the absence of clinically manifest
ocular inflammation. This increased LC presence and
activation did not appear to be associated with articular
inflammatory disease activity, but correlated with the
severity of hypolacrimation, and was abrogated by
GCS therapy.
With the development of histochemistry and elec-
tron microscopy, a huge body of evidence was accumu-
lated on corneal immunology, which required the
revision of the tenet on the cornea as an immune privi-
leged tissue.17 Various immune cells were demonstrated
to reside in the cornea, including LCs.7 In healthy con-
ditions, LCs are scarce in the centre of the cornea.
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Figure 1. Confocal microscopic image of the corneal centre (A) and the periphery (C) in the control group. Note that central area is
without obvious signs of the presence of Langerhans cells (LC) [LC morphology (LCM): score 0], while in the periphery some non-
activated LCs (white arrow indicating a score 1 LC) can be seen accompanied by sub-basal nerves. (B) Corneal centre with gathering
LCs with small processes (white arrowhead shows a score 2 LC). (D) Long and interdigitating LCs (empty arrow pointing at a score 3
LC) situated in a network-like fashion in the periphery indicating mature form of this cell type in the rheumatoid arthritis (RA) group.
Table 2. Dry eye-related parameters in different subgroups of RA patients. Data are expressed as mean SD. Comparisons
between healthy individuals and RA patients, as well as between RA patient subgroups, were made with Cochran-Armitage trend tests
in the case of LIPCOF values. Continuous variables were compared using t-tests. Prior to analysis the distribution of variables was
checked graphically and, if necessary, variables were Box-Cox transformed prior to the analysis.
Study group OSDI LIPCOF
Schirmer
(mm/5 min) TBUT [s]
Healthy individuals 11.71 8.73 1.29 0.55 11.96 3.14 11.04 3.32
All RA patients 24.46 17.50a 1.35 0.68 9.74 7.41 9.28 3.86c
RA patients according to DAS28 score
2.6 (53.8%) 25.83 18.66 1.36 0.68 10.23 5.72 9.41 3.50
>2.6 (46.2%) 22.87 16.30 1.33 0.70 9.17 9.09 9.13 4.32
RA patients according to anti-TNF-a therapy
Yes (44.2%) 28.28 19.11 1.26 0.62 9.63 5.98 8.80 3.54
No (55.8%) 21.44 15.79 1.41 0.73 9.83 8.48 9.66 4.12
RA patients according to glucocorticosteroid therapy
Yes (34.6%) 23.63 15.83 1.39 0.78 7.50 5.50 8.83 3.78
No (65.4%) 24.90 18.54 1.32 0.64 10.93 8.06b 9.52 3.94
aP< 0.05 versus healthy individuals.
bP< 0.1 versus RA patients in the corresponding subgroup.
cP< 0.1 versus healthy individuals.
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Upon different triggers, however, LCs migrate to the
centre of the cornea and transform into an active par-
ticipant of the corneal immune response by the forma-
tion of dendrite-like processes and expression of
co-stimulatory molecules, including CD80 and
CD86.18 LCs are found in a greater number in several
inflammation-related conditions, including contact lens
wearers3 and Thygeson’s superficial punctate kera-
titis,8,9 and also in experimental conditions.19,20 The
elevation of LC and leukocyte density both in the
centre and the periphery of the cornea has already
been described in patients with Sjögren’s syndrome.21
In this study we have used confocal microscopy, a
recently developed device that is non-invasive and cap-
able of visualizing the ultrastructure of the ocular sur-
face, including the meibomian glands at a cell level.22
Reliability and specificity of the device have been
acknowledged in a study by Imre et al.;23 however,
there are some limitations when it is used on corneas
with decreased transparency. We aimed to investigate
the density and morphology of corneal LCs for their
presumed role in ocular surface diseases and their prop-
erties to indicate the corneal homeostasis. LCs reside
almost exclusively in the superficial cornea and can be
distinguished from leukocytes through their appear-
ance. They have an extraordinary capacity to stimulate
naı̈ve T cells and are recognized as essential regulators
of both the innate and acquired arms of the immune
system.7,21 We have observed that, in contrast with
healthy subjects, LC density was elevated markedly
and found to reside in the corneal centre of RA
patients, even without overlapping Sjögren’s syndrome
or in the absence of overt eye symptoms. Additionally,
more than half of these LCs showed an activated
phenotype with small or long projections.
It has been shown that the recruitment and matur-
ation of LCs can be induced by several pro-inflamma-
tory cytokines, including IL-1a, TNF-a, IL-6, IL-8 and
IL-12.10,23 Both IL-1 inhibitors, anti-TNF-a therapy
and GCS suppressed the LC migration in vitro effect-
ively.24,25 Our clinical results also suggest this possible
inhibitory effect of GCS therapy on the activation
of LCs in RA.
Corneal immune status may be strongly interrelated
with dysfunctional tear production, but the causative
relationship has still not been established. It has long
been known that dry eye is more common among
patients with autoimmune diseases,1 but the precise
pathophysiologic mechanism is still unclear.
Hyposecretory conditions, such as Sjögren’s syndrome,
through the reduced moisturization of the ocular sur-
face, may initiate or contribute to the development of
dry eye. Corneal morphological changes like thinning
of the cornea, lower density of superficial epithelial
cells, fewer sub-basal nerves and greater nerve tortuos-
ity have been described in association with dry eye26
and in RA subjects.27 Inadequate moisturization leads
to increased apoptosis and further induction of pro-
inflammatory cytokines, including IL-1, 6, 8 and
TNF-a, which have been found to be overexpressed
and to accumulate in the ocular surface. In turn,
these cytokines are thought to have the capacity to
decrease tear production via neuronal and hormonal
effects.28,29 Indeed, we found decreased tear production
in RA patients who had at least moderate RA activity.
Theoretically, higher clinical activity in RA results in
Table 3. Confocal microscopy results in different subgroups of RA patients. Data are expressed as mean SD.
Comparisons between healthy individuals and RA patients, as well as between RA patient subgroups, were made with
Cochran-Armitage trend tests in case of LCM values. Continuous variables were compared using t-tests. Prior to analysis
the distribution of variables was checked graphically and, if necessary, variables were Box-Cox transformed prior to the
analysis.
Study group LC centre (cell/mm2) LC periphery (cell/mm2) LCM centre LCM periphery
Healthy individuals 23.85 33.81 69.29 33.26 0.96 0.75 2.42 0.50
All RA patients 68.15 71.27a 126.8 104.6a 1.54 0.78a 2.60 0.60
RA patients according to DAS28 score
2.6 (53.8%) 63.13 66.20 134.3 121.5 1.50 0.75 2.68 0.48
>2.6 (46.2%) 74.01 77.80 117.9 82.15 1.58 0.83 2.50 0.72
RA patients according to anti-TNF-a therapy
Yes (44.2%) 69.22 69.61 124.8 117.2 1.48 0.67 2.65 0.49
No (55.8%) 67.30 73.78 128.3 95.43 1.59 0.87 2.55 0.69
RA patients according to glucocorticosteroid therapy
Yes (34.6%) 37.37 31.16 86.70 47.16 1.50 0.92 2.56 0.78
No (65.4%) 84.45 80.99b 148.0 120.0c 1.56 0.70 2.62 0.49
aP< 0.05 versus healthy individuals.
bP< 0.1 versus RA patients in the corresponding subgroup.
cP< 0.05 versus RA patients in the corresponding subgroup.
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higher systemic inflammation, which may also increase
the secretion of pro-inflammatory cytokines in tears.
The possible higher amount of these cytokines in the
tears of RA patients with higher disease activity might
impair tear production and it might partly explain the
dry eye mechanism without the presence of true over-
lapping Sjögren’s syndrome. It is of importance to
emphasize that none of the RA patients had overlap-
ping Sjögren’s syndrome. Our results are in accordance
with the results of Villani et al.,27 which is of particular
interest because some reports suggest that there are
profound aetiologic and pathogenic differences between
keratoconjunctivitis sicca in patients with RA with sec-
ondary Sjögren’s syndrome, and patients with RA
without secondary Sjögren’s, though they lack manifest
differences in the clinical indicators.30 Rather, our data,
along with that of Villani et al.,27 suggest that these
alterations of the cornea are associated with the sys-
temic inflammatory effect of the disease than a specific
pathogenic difference in KCS in patients with or with-
out Sjögren’s syndrome. Also, our data, together with
that of Villani et al., 27 may lend itself to the identifi-
cation of some indices of disease activity on the ocular
surface that could be compared with the indices of
activity of the systemic disease. Our results are also in
agreement with previous results, which showed that
ocular surface LCs are essential for T cell-mediated
dry eye.31 Our results also support the systemic multi-
organ-related feature of RA affecting the eye. Recent
data showed an increased accumulation of dendritic
cells (DCs) in the synovial fluid of patients with active
RA and the decrease in DCs in the peripheral blood.
Because DCs migrate to sites of inflammation, lack of
them in the peripheral blood of patients with active RA
may be owing to the recruitment of DCs at the syno-
vium. According to our results a similar process might
act also in the cornea of patients with mild or moderate
active RA.32 We have also demonstrated that low-dose,
continuously-used oral GCS therapy can significantly
reduce the density of LCs, both in the central and per-
ipheral parts of the cornea. Low-dose, continuously-
used oral GCS therapy also inhibits the dendrite-form-
ing ability of central LCs. These results also suggest
that the immunosuppressive effects of GCS also affect
the corneal immune mechanisms in RA.
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Ophthalmol Vis Sci 2011; 52: 933–939.
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